Compare · MDLN vs SENS
MDLN vs SENS
Side-by-side comparison of Medline Inc. (MDLN) and Senseonics Holdings Inc. (SENS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and SENS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $44.40B, about 41.7x SENS ($1.07B).
- Over the past year, MDLN is down 17.1% and SENS is down 32.7% - MDLN leads by 15.6 points.
- SENS has been more active in the news (23 items in the past 4 weeks vs 20 for MDLN).
- MDLN has more recent analyst coverage (25 ratings vs 7 for SENS).
- Company
- Medline Inc.
- Senseonics Holdings Inc.
- Price
- $33.80+0.58%
- $7.13+6.97%
- Market cap
- $44.40B
- $1.07B
- 1M return
- -19.55%
- +32.62%
- 1Y return
- -17.07%
- -32.69%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- AMEX
- IPO
- 2025
- News (4w)
- 20
- 23
- Recent ratings
- 25
- 7
Senseonics Holdings Inc.
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to 90 and 180 days. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)
Latest SENS
- Senseonics Holdings Inc. filed SEC Form 8-K: Other Events
- Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems
- SEC Form SD filed by Senseonics Holdings Inc.
- Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026
- Chief Medical Officer Kaufman Francine was granted 63,177 shares, increasing direct ownership by 54% to 181,067 units (SEC Form 4)
- GC & Corp. Development Advisor Horton Kenneth L was granted 157,943 shares, increasing direct ownership by 115% to 295,057 units (SEC Form 4)
- Chief Operating Officer Jain Mukul was granted 270,759 shares, increasing direct ownership by 110% to 517,057 units (SEC Form 4)
- Director Fiorentino Edward was granted 9,852 shares, increasing direct ownership by 13% to 83,339 units (SEC Form 4)
- Director Defalco Stephen P was granted 9,852 shares, increasing direct ownership by 10% to 111,019 units (SEC Form 4)
- Director Roeder Douglas A was granted 9,852 shares, increasing direct ownership by 7% to 154,487 units (SEC Form 4)